MiR-26 can also suppress atrial fibrillation (AF) and cardiomyocyte hypertrophy by targeting β-MHC, GSK3β, GATA4, KCNJ2, and PLCβ1 [58]. This evidence concerns the gene PLCB1 and atrial fibrillation.